In the SAVOR-TIMI 53 trial, which was originally performed to assess the cardiovascular safety of saxagliptin, Leibowitz and colleagues recently reported that DPP4 inhibition may attenuate the progression of diabetes (142). This evidence concerns the gene DPP4 and diabetes mellitus.